Fasiha Kanwal

1 month ago | digitalcommons.library.tmc.edu | Fasiha Kanwal |Jennifer Kramer |Yu-Xiao Yang |Yumei Cao

IMPORTANCE: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasing cause of cirrhosis. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are effective in improving liver inflammation in patients with MASLD. OBJECTIVE: To determine whether use of GLP-1 RAs is associated with lower risk of developing cirrhosis and its complications, including decompensation and hepatocellular cancer (HCC), among patients with MASLD.

Dec 4, 2024 | digitalcommons.library.tmc.edu | Fasiha Kanwal |Ruben Hernaez |Yan Liu |Thomas Taylor

IMPORTANCE: Organ scarcity means few patients with advanced liver disease undergo a transplant, making equitable distribution all the more crucial. Disparities may arise at any stage in the complex process leading up to this curative therapy. OBJECTIVE: To examine the rate of and factors associated with referral, wait-listing, and receipt of liver allografts.

Sep 16, 2024 | jamanetwork.com | Fasiha Kanwal |Jennifer Kramer |Ronald Samuel

Key PointsQuestion  Is use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) associated with lower incidence of cirrhosis and its complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)?

Sep 16, 2024 | jamanetwork.com | Fasiha Kanwal |Jennifer Kramer |Ronald Samuel

Key PointsQuestion  Is use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) associated with lower incidence of cirrhosis and its complications in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)?